PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim

PharmAthene, Inc. announced Thursday that the United States Food and Drug Administration (FDA) has provided formal consent for PharmAthene to reinitiate clinical testing of its anthrax anti-toxin, Valortim, after lifting the partial clinical hold placed on the program in late 2009.
CNBC